1.
Chem Commun (Camb)
; 55(53): 7671-7674, 2019 Jun 27.
Artigo
em Inglês
| MEDLINE
| ID: mdl-31204425
RESUMO
Herein we report the construction of a nanoparticle-based drug delivery system which targets a key regulator in tumour angiogenesis. We exploit a Variable New Antigen Receptor (VNAR) domain, conjugated using site-specific chemistry, to direct poly lactic acid-co-glycolic acid-polyethylene glycol (PLGA-PEG) nanoparticles to delta like canonical Notch ligand 4 (DLL4). The importance of site-specific chemistry is demonstrated.